Pocenbrodib - Pathos
Alternative Names: FT-7051; P-300Latest Information Update: 30 Jun 2025
At a glance
- Originator FORMA Therapeutics
- Developer Pathos
- Class Antineoplastics; Small molecules
- Mechanism of Action P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from the preclinical studies Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 Feb 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT06785636)
- 07 Feb 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06785636)